Abstract:INTRODUCTION: Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Genetically, MB can be divided into four subgroups of which the SHH subtype histologically shows nodular architecture. Within this nodular architecture, there are islands of mature cells, with more abundant neuropil and a low proliferation rate, scattered among sheets of primitive cells. METHODS: We performed laser capture microdissection followed by whole transcriptome analysis, spatial transcriptomics using Digital Spatial Profiling, whole genome DNA methylation and ChIP-Seq analysis of mature and primitive areas from 8 medulloblastomas. We developed a genetically-engineered mouse model of SHH MB showing spontaneous maturation and lack of maturation with a conditional EZH2 genetic ablation or EZH2 overactivation respectively. Finally, we developed a fucoidan-based nanoparticle drug delivery across the blood brain barrier (BBB) for targeted molecular inhibition. RESULTS: Using whole transcriptome and DNA methylation analysis, we identified ∼120 differentially expressed genes between primitive and mature regions with enrichment for genes regulated by H3K4me3 and H3K27me3. ChIP-Seq analysis showed striking differences in H3K27me3 enrichment between primitive and mature medulloblastoma cells including at the EZH2 locus. Medulloblastoma specific EZH2 genetic ablation resulted in diffuse tumor cell differentiation and prolonged survival in mice (n = 10 per group, log-rank p = 0.01). Conversely, conditional EZH2 (Y641F) activation prevented medulloblastoma differentiation. A fucoidan-based nanoparticle successfully delivered the EZH2 inhibitor (EPZ-6438) across the murine BBB to achieve significant extension of mouse survival (median 70 days compared to 21 days in control mice; *p = 0.01, Mantel-Cox). CONCLUSIONS: Spontaneous maturation of medulloblastoma cells can be induced by inhibition of EZH2. Fucoidan-based nanoparticle delivery systems allows tumor specific targeted delivery across the BBB extending survival in mice.

Research progress of Sonic Hedgehog signaling pathway and its targeted inhibitors in ;medulloblastoma

An Epigenetic Switch Induced by Shh Signalling Regulates Gene Activation During Development and Medulloblastoma Growth

Cdc14B/Cyclin B1 signaling modulates the pathogenesis of sonic hedgehog subtype medulloblastoma

MEKK2 and MEKK3 Suppress Hedgehog Pathway-Dependent Medulloblastoma by Inhibiting GLI1 Function

Sonic hedgehog signaling: Alternative splicing and pathogenic role in medulloblastoma

Dual Regulatory Functions of SUFU and Targetome of GLI2 in SHH Subgroup Medulloblastoma.

A highlight on Sonic hedgehog pathway

Sonic hedgehog signalling pathway in CNS tumours: its role and therapeutic implications

270 Inducing Neural Maturation and Increasing Survival in SHH Medulloblastoma Using EZH2 Inhibition in a Mouse Model

Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma

The transcriptional landscape of Shh medulloblastoma

A Simple and Scalable Zebrafish Model of Sonic Hedgehog Medulloblastoma

Sonic Hedgehog Signaling in Organogenesis, Tumors, and Tumor Microenvironments

The role of Shh signalling pathway in central nervous system development and related diseases

Small-molecule modulators of the Sonic Hedgehog signaling pathway

Targeting of Sonic Hedgehog-Gli Signaling: A Potential Therapeutic Target for Patients with Breast Cancer

Ezh2 Delays Activation of Differentiation Genes During Normal Cerebellar Granule Neuron Development and in Medulloblastoma

Developmental basis of SHH medulloblastoma heterogeneity

O-GlcNAcylation promotes cerebellum development and medulloblastoma oncogenesis via SHH signaling

scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy

Aberrant FGF signaling promotes granule neuron precursor expansion in SHH subgroup infantile medulloblastoma